Considered as one of the greatest threats to mankind, infectious diseases are responsible for 15% of all deaths worldwide, and transmission rates remain high due to increasingly transient and concentrated global populations (source WHO). Through science and innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson aims to deliver an end-to-end approach to prevent, treat and cure infectious diseases. It is our goal to ensure a future where we can hopefully prevent the spread of infectious diseases and eliminate the burden they place on global health, but we can’t do it alone.
Don't miss this lively discussion featuring leaders in the field who can share the opportunities and challenges of medicines aiming to help fight infectious diseases worldwide, as well as in Europe.
*This program is a product of a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
17:50 Panel Discussion
- Bart van Zijll Langhout, PhD (Moderator) | Vice President, Strategic Alliances EMEA & Janssen The Netherlands Campus Lead, Janssen
- Coen Breedveld | Co-founder, Levels Diagnostics
- Marc Bonten, M.D. | Head, Department of Medical Microbiology, UMC Utrecht
- Marion Koopmans, DVM, PhD | Head of the Viroscience, Department of the Erasmus MC Rotterdam
- Peter Reiss, M.D., PhD | Professor of Medicine, UMC Amsterdam
- Meta Roestenberg, PhD | Infectious Disease Specialist, Department of Infectious Diseases, Leiden University Medical Center
- Johan Van Hoof, M.D. | Global Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen
Marc Bonten, M.D., is head of the Department of Medical Microbiology and leading the research group of infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care, both at the UMC Utrecht, where he is professor of molecular epidemiology of infectious diseases. He is also the Scientific Director of the research theme "Tackling Antimicrobial Resistance" of the Netherlands Centre for One Health, and board member of the Netherlands Antibiotic Development Platform.
Professor Marion Koopmans, DVM PhD focuses on global population level impact of rapidly spreading zoonotic virus infections, with special emphasis on foodborne transmission. Her research focuses on unravelling the modes of transmission of viruses among animals and between animals and humans, and the use of pathogenic genomic information to unravel these pathways and to signal changes in transmission or disease impact
Peter Reiss is Professor of Medicine at the Amsterdam UMC in Amsterdam, the Netherlands, where he holds a joint appointment in the Department of Global Health and the division of Infectious Diseases. He has been Director of the Netherlands HIV Monitoring Foundation since February 2013. He also serves on the Scientific Advisory Boards of the Agence Nationale de Recherches sur de Sida et les hepatitis virales (ANRS) and the Swiss HIV Cohort Study, as well as on the Steering Committees of the D:A:D study, the Antiretroviral Therapy Cohort Collaboration and the EuroSida Study.
Meta Roestenberg is physician-scientist in the Department of Parasitology and as clinician within the Department of Infectious Diseases at the Leiden University Medical Center. She is currently leading a group of translational scientists investigating the efficacy of a genetically attenuated malaria vaccine and developing human models for Schistosoma mansoni and Necator americanus.
Johan Van Hoof, M.D., is the Global Therapeutic Area Head, IDV Vaccines, Janssen R&D and Managing Director, Janssen Vaccines & Prevention, B.V. Since 2011, he has been overseeing research & development at Janssen Vaccines as Managing Director. In this role, Johan is tirelessly leading his world-class team to develop transformational vaccines which will prevent, intercept, treat and cure life-threatening infectious diseases. Johan continues to advance Janssen’s efforts in this area, utilizing cutting-edge technology and strategic collaborations to drive research and development forward.
As Campus Lead Bart ensures internal strategic alignment on shared opportunities and interests. As the external face of the Janssen The Netherlands Campus, he represents the Janssen Campus towards internal and external stakeholders to strengthen the position and contribution of the Janssen companies in The Netherlands
In the other part of his current role Bart leads the EMEA Strategic Alliances function and establishes innovative partnerships with internal & external stakeholders and business partners to accelerate selected strategic opportunities into concrete ideas and initiatives and drive implementation.
